Joining a global M&A spree, Astellas reserves $2B for a spate of new biotech acquisitions
Astellas is joining Takeda and a growing pack of global drug hunters in the M&A game.
Company execs are telling reporters in Japan that they …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
